Descrizione del progetto
Le centrali elettriche a biomasse da microalghe producono migliori terapie antitumorali
La domanda di proteine farmaceutiche ricombinanti sta crescendo a livello globale e l’uso di microrganismi come piccoli bioreattori per una produzione rapida ed economica è un importante settore di ricerca. Le microalghe, come le linee cellulari dei mammiferi, consentono modifiche post-trascrizionali e post-traslazionali, un’elevata qualità di produzione e un’elevata resa proteica. Tuttavia, a differenza delle colture cellulari di mammiferi, offrono una produzione rapida su larga scala, bassi costi complessivi, basso rischio di contaminazione e facilità di riproduzione e distribuzione. MABIOS ha sviluppato una piattaforma di microalghe per la produzione di biofarmaci antitumorali che potrebbero ridurre i costi di trattamento per milioni di pazienti in tutto il mondo. Il finanziamento dell’UE offre l’opportunità di sviluppare il miglior piano aziendale, soddisfare i requisiti normativi e immettere la piattaforma sul mercato.
Obiettivo
Manufacturing costs remain one of the major obstacles to providing effective treatment of cancer patients. Anticancer agents are often complex biopharmaceuticals that are expensive to manufacture, requiring use of living cell lines with difficult-to-control production processes, limited yields and time-consuming purification steps. There is an urgent unmet need for an improved manufacturing process of biopharmaceuticals, to meet the high demand and lower the price of oncologic treatments. We will revolutionize the way biopharmaceuticals are produced by developing a microalgae based biorefinery platform. These biorefineries will utilize genetically engineered microalgae to efficiently produce pharmaceutical agents. Microalgae are photosynthetic micro-organisms that have unique advantages as biopharmaceutical production systems, including high growth rate, ease of cultivation and low growth costs, enabling cost effective and scalable yield of active ingredients. These will be recombinant proteins, small molecules or therapeutic peptides, starting with Paclitaxel as showcase, one of the world’s best sold anticancer drugs used as the first line treatment of a several solid tumours. Our platform has the potential to become the new manufacturing method of choice for production of highly needed biopharmaceuticals. Microalgae Works is an ambitious Dutch start-up with the mission to make anticancer treatment affordable for every patient through a drastic reduction of manufacturing costs. We are supported by leading companies in the field of biomanufacturing. The MABIOS project will (1) create a clear overview of the market opportunity for micro-algae based production of paclitaxel, (2) develop a de-risked plan for the technical development of our platform, (3) evaluate the necessary regulatory roadmap to enter the market, and (4) formulate an investor-proof business plan. We aim to become the frontrunner in biopharmaceutical production utilizing microalgae.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
2333 CW LEIDEN
Paesi Bassi
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.